# Masahiro Tsuboi
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/masahiro-tsuboi/
## Facts
| Field | Value |
| --- | --- |
| Citations | 32,191 |
| Field | Lung Cancer Diagnosis and Treatment |
| h-index | 73 |
| i10-index | 260 |
| Last Known Institution | National Cancer Center Hospital East |
| OpenAlex ID | https://openalex.org/A5045498137 |
| ORCID iD | https://orcid.org/0000-0003-3031-5807 |
| Works | 746 |
## Researcher papers
Showing 12 of 13.
- [International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma](https://scholariq.org/papers/international-association-for-the-study-of-lung-cancer-american-thoracic-society/)
- [Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial](https://scholariq.org/papers/segmentectomy-versus-lobectomy-in-small-sized-peripheral-non-small-cell-lung/)
- [Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer/)
- [Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments](https://scholariq.org/papers/lactic-acid-promotes-pd-1-expression-in-regulatory-t-cells-in-highly-glycolytic/)
- [The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies](https://scholariq.org/papers/the-pd-1-expression-balance-between-effector-and-regulatory-t-cells-predicts-the/)
- [Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-resected-i-egfr-i-mutated-nsclc/)
- [Interstitial Lung Disease in Japanese Patients with Lung Cancer](https://scholariq.org/papers/interstitial-lung-disease-in-japanese-patients-with-lung-cancer/)
- [Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial](https://scholariq.org/papers/adjuvant-osimertinib-for-resected-egfr-mutated-stage-ib-iiia-non-small-cell-lung/)
- [A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer](https://scholariq.org/papers/a-single-arm-study-of-sublobar-resection-for-ground-glass-opacity-dominant/)
- [Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-v-15-32-of-gefitinib-versus-docetaxel-in-previously-treated/)
- [Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer](https://scholariq.org/papers/blockade-of-egfr-improves-responsiveness-to-pd-1-blockade-in-i-egfr-i-mutated/)
## Researcher topics
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
## Researcher university
- [National Cancer Center Hospital East](https://scholariq.org/institutions/national-cancer-center-hospital-east/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.